References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Pavelka, Karel; Bruyère, Olivier ULg; Cooper, Cyrus et al

in Drugs & Aging (2016)

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been ... [more ▼]

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures
Ethgen, Olivier ULg; Hiligsmann, Mickaël; Burlet, Nansa et al

in Osteoporosis International (2016), 27

Summary: Titrated supplementations with vitamin D-fortified yogurt, based on spontaneous calcium and vitamin D intakes, can be cost-effective in postmenopausal women with or without increased risk of ... [more ▼]

Summary: Titrated supplementations with vitamin D-fortified yogurt, based on spontaneous calcium and vitamin D intakes, can be cost-effective in postmenopausal women with or without increased risk of osteoporotic fractures. Introduction: The objective of this study is to assess the costeffectiveness of the vitamin D-fortified yogurt given to women with and without an increased risk of osteoporotic fracture. Methods: Avalidated cost-effectiveness microsimulation Markov model of osteoporosis management was used. Three personalized supplementation scenarios to reflect the Ca/Vit D needs taking into account the well-known variations in dietary habits and a possible pharmacological supplementation in Ca/ Vit D, given above or in combination with anti-osteoporosis medications: one yogurt per day, i.e., 400 mg of Ca+200 IU of Vit D (scenario 1 U), two yogurts per day, i.e., 800 mg of Ca+ 400 IU of Vit D (scenario 2 U), or three yogurts per day, i.e., 1, 200 mg of Ca+600 IU of Vit D (scenario 3 U). Results: One yogurt is cost-effective in the general population above the age of 70 years and in all age groups in women with low bone mineral density (BMD) or prevalent vertebral fracture (PVF). The daily intake of two yogurts is cost-effective above 80 years in the general population and above 70 years in the two groups of women at increased risk of fractures. However, an intake of three yogurts per day is only cost-effective above 80 years old in the general population, as well as in women with low BMD or PVF. Conclusions: Our study is the first economic analysis supporting the cost-effectiveness of dairy products, fortified with vitamin D, in the armamentarium against osteoporotic fractures. [less ▲]

Detailed reference viewed: 14 (6 ULg)
Full Text
Peer Reviewed
See detailEffects of Dairy Products Consumption on Health: Benefits and Beliefs-A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
Rozenberg, Serge; Body, Jean-Jacques; Bruyère, Olivier ULg et al

in Calcified Tissue International (2016), 98(1), 1-17

Dairy products provide a package of essential nutrients that is difficult to obtain in low-dairy or dairy-free diets, and for many people it is not possible to achieve recommended daily calcium intakes ... [more ▼]

Dairy products provide a package of essential nutrients that is difficult to obtain in low-dairy or dairy-free diets, and for many people it is not possible to achieve recommended daily calcium intakes with a dairy-free diet. Despite the established benefits for bone health, some people avoid dairy in their diet due to beliefs that dairy may be detrimental to health, especially in those with weight management issues, lactose intolerance, osteoarthritis, rheumatoid arthritis, or trying to avoid cardiovascular disease. This review provides information for health professionals to enable them to help their patients make informed decisions about consuming dairy products as part of a balanced diet. There may be a weak association between dairy consumption and a possible small weight reduction, with decreases in fat mass and waist circumference and increases in lean body mass. Lactose intolerant individuals may not need to completely eliminate dairy products from their diet, as both yogurt and hard cheese are well tolerated. Among people with arthritis, there is no evidence for a benefit to avoid dairy consumption. Dairy products do not increase the risk of cardiovascular disease, particularly if low fat. Intake of up to three servings of dairy products per day appears to be safe and may confer a favourable benefit with regard to bone health. [less ▲]

Detailed reference viewed: 29 (18 ULg)
Full Text
Peer Reviewed
See detailLe couplage « Micro-crédit, Micro-assurance santé et Offre des soins » peut améliorer l’accessibilité aux soins de santé de qualité en milieu urbain africain : Résultats d’une expérience menée dans la zone de santé de Bandalungwa à Kinshasa, Congo.
Manzambi Kuwekita, Joseph ULg; Gosset, Christiane ULg; Guillaume, Michèle ULg et al

in Médecine et Santé Tropicales (2015), 25

Summary This study, based on a survey carried out in 2008, examines how coupling «microcredit, micro-insurance and health care» can improve access to quality care in the health zone of Bandalungwa, in ... [more ▼]

Summary This study, based on a survey carried out in 2008, examines how coupling «microcredit, micro-insurance and health care» can improve access to quality care in the health zone of Bandalungwa, in Kinshasa. The bivariate analysis shows a significant association between the increase in purchasing power and realization of benefit (p = 0, 001), achievement of benefit and savings (p = 0, 000) savings and insurance health and improved access to health care: according to the main results, 68.8 %t of borrowers reported an increase in their purchasing power which 81.8% making benefit. Those with savings were 24.7 times more likely to contribute to a health insurance scheme than those without; 71.9% of those who have regularly contributed to health insurance have improved their access to care. Coupling microcredit, health microinsurance and health care can improve access to quality health care at lower cost. This suggests the integration of health insurance in the primary health care system. [less ▲]

Detailed reference viewed: 124 (36 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
Reginster, Jean-Yves ULg; Cooper, Cyrus; Rizzoli, René et al

in Aging Clinical and Experimental Research (2015)

Purpose: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a ... [more ▼]

Purpose: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities. Methods: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication. Results A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a pleais made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia. Conclusions : The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk. [less ▲]

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailPublic health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures
Ethgen, Olivier ULg; Hiligsmann, Mickaël; Burlet, Nansa et al

in Archives of Public Health (2015)

Background: Dietary sources of calcium and vitamin D are recommended as a first-line strategy in prevention of osteoporosis-related fractures but their public health and economic impact has never been ... [more ▼]

Background: Dietary sources of calcium and vitamin D are recommended as a first-line strategy in prevention of osteoporosis-related fractures but their public health and economic impact has never been studied. Methods: We designed a population-based model to forecast the potential health outcomes and medical effectiveness of the daily administration of dairy supplements containing 800 IU of vitamin D and 1 g of calcium in cohorts of subjects, from both genders, aged 50, 60, 70 and 80 years. Annual costs of dairy products were tested at €150, €250 and €350. Results: In total, the daily intake of vitamin-D rich dairy products reduces by 30,376 and 16,105 events the number of osteoporotic fractures in women and men respectively and permits to gain 6605 and 6144 life-years, in women and men respectively. This intervention is cost-effective from 70 years on in the general population and from 60 years on in patients at increased risk of osteoporotic fractures. Conclusion: The recommendation to use dairy products as the preferred source of calcium and vitamin D in aging males and females is supported by public health and health economic analyses. [less ▲]

Detailed reference viewed: 5 (3 ULg)
Full Text
Peer Reviewed
See detailSarcopenia as a public health problem
Bruyère, Olivier ULg; Beaudart, Charlotte ULg; Locquet, Médéa ULg et al

in European Geriatric Medicine (2015)

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an ... [more ▼]

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an effective treatment. In this paper, we review the main current literature on sarcopenia in order to assess whether this geriatric syndrome could be considered as a major public health problem. Our review highlights that based on its prevalence, its clinical consequences, the limitations of the current available treatments as well as on the fact that many frail patients are affected by this geriatric syndrome, sarcopenia should be considered as a health priority by all interested parties in order to reduce its burden. [less ▲]

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailQualité de vie du patient sarcopénique : apport de l’étude liégeoise SarcoPhAge
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; PETERMANS, Jean ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2015), 13(4), 391-5

The consequences of sarcopenia on quality are difficult to evaluate and consequently are quite poorly studied. The few studies assessing the quality of life in sarcopenic subjects currently use generic ... [more ▼]

The consequences of sarcopenia on quality are difficult to evaluate and consequently are quite poorly studied. The few studies assessing the quality of life in sarcopenic subjects currently use generic quality of life questionnaires such as SF36 and EQ5D. The SarcoPhAge study, conducted on a cohort developed in Liège including 534 subjects of 65 years or older, suggested that sarcopenic subjects present a significant worse quality of life in the domains of physical function compared to nonsarcopenic subjects. Generic tools do not cover exhaustively all the areas of potential dysfunction concerned in this geriatric syndrome. Yet, there is no specific and validated quality of life questionnaire for sarcopenia. It would be useful to have at our disposal a sarcopenia specific quality of life questionnaire to assess not only the prospective quality of life of sarcopenic subjects but also to assess the efficacy and the rele [less ▲]

Detailed reference viewed: 15 (8 ULg)
Full Text
Peer Reviewed
See detailThe effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
PAPAPOULOS, S.; LIPPUNER, K.; ROUX, C. et al

in Osteoporosis International (2015), 26(12), 2773-2783

Summary: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with ... [more ▼]

Summary: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with persistent reduction of bone turnover, continued increases in bone mineral density, low fracture incidence, and a favorable benefit/risk profile. Introduction: This study aims to report the results through year 5 of the FREEDOM Extension study, representing up to 8 years of continued denosumab treatment in postmenopausal women with osteoporosis. Methods : Women who completed the 3-year FREEDOM study were eligible to enter the 7-year open-label FREEDOM Extension in which all participants are scheduled to receive denosumab, since placebo assignment was discontinued for ethical reasons. A total of 4550 women enrolled in the Extension (2343 long-term; 2207 cross-over). In this analysis, women in the long-term and cross-over groups received denosumab for up to 8 and 5 years, respectively. Results Throughout the Extension, sustained reduction of bone turnover markers (BTMs) was observed in both groups. In the long-term group, mean bone mineral density (BMD) continued to increase significantly at each time point measured, for cumulative 8-year gains of 18.4 and 8.3 % at the lumbar spine and total hip, respectively. In the cross-over group, mean BMD increased significantly from the Extension baseline for 5-year cumulative gains of 13.1 and 6.2 % at the lumbar spine and total hip, respectively. The yearly incidence of new vertebral and nonvertebral fractures remained low in both groups. The incidence of adverse and serious adverse events did not increase over time. Through Extension year 5, eight events of osteonecrosis of the jaw and two events of atypical femoral fracture were confirmed. [less ▲]

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailAssessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey
Bruyère, Olivier ULg; Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg et al

in European Geriatric Medicine (2015)

Introduction: Several tools are available for the assessment of muscle mass, muscle strength and physical performance in clinical research. However, few data are available on the usage of these tools in ... [more ▼]

Introduction: Several tools are available for the assessment of muscle mass, muscle strength and physical performance in clinical research. However, few data are available on the usage of these tools in clinical practice. Methods: This study aimed to assess their usage by means of a large online international survey. Since sarcopenia is a specific condition where the assessment of muscle mass, muscle strength and physical performance is important, the survey also assessed the tools used for the diagnosis of this geriatric syndrome. Results: The survey was completed by 255 clinicians from 55 countries across 5 continents. Among these clinicians with geriatrics, rheumatology and endocrinology as major fields of interest, 53.3% assess muscle mass in daily practice, 54.5% muscle strength and 71.4% physical performance. However, the tools used are very different and no single tool is used by all clinicians. The tools and the cut-off values used by clinicians to diagnose sarcopenia are also heterogeneous. Conclusion: Because some tools used for the assessment of muscle mass, muscle strength or physical performance in daily practice are less validated than others, a greater awareness from the clinicians of the importance of using appropriate tools is needed [less ▲]

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailLe tradipraticien est un acteur incontournable dans l’offre des soins de santé en territoire péri-urbain : équilibre entre légitimité et illégalité ?
Manzambi Kuwekita, Joseph ULg; Mbadu Kivuidi, Véronique; Bruyère, Olivier ULg et al

in Halleux, Jean-Marie; Bogaert, Jan (Eds.) Territoires Périurbains (2015)

Summary This study examines people’s and public actors’s perception of traditional healers in Kisenso, and their potential integration into the health system. The findings of this study are based on focus ... [more ▼]

Summary This study examines people’s and public actors’s perception of traditional healers in Kisenso, and their potential integration into the health system. The findings of this study are based on focus groups conducted in 2013. According to the key results of this study, 100% of participants acknowledge the existence of traditional practitioners and all have used them. 80% found the care provided by these healers to be effective. However, the study participants found them to be lacking in hygiene in their handling of products. The use of traditional healers is justified in particular by the effectiveness of care, the type of illness suffered, the possibility of credit payment and their proximity. Public actors recognize both the existence of traditional healers and their effectiveness. They deplore their clandestine operation. Traditional healers claiming to be GPs (60%) and specialists (40%) say they work illegally because of the cost of administrative acts and their mistrust of intellectuals and biomedical practitioners. They complain about the insolvency of their patients who do not honor their commitments. For an effective integration of traditional healers in the health system, it would be useful to remove administrative barriers imposed on them for a balance between ancestral legitimacy and illegality in which they work, give them access to training, accept them as full participants in the health system, and explore the possibilities of contracting. [less ▲]

Detailed reference viewed: 51 (23 ULg)
Full Text
Peer Reviewed
See detailPourcentage de femmes atteignant des T-scores de DMO non ostéoporotiques au rachis lombaire (RL) et à la hanche totale (HT) après 8 ans de traitement par denosumab (DMAb)
Ferrari, S.; Libanati, C.; Lin, J. et al

in Revue du Rhumatisme (2015, November), 82(S1), 35-36

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailTraitement par denosumab chez des hommes à masse osseuse basse: résultats à 24 mois de l'étude ADAMO
Chapurlat, R.; Langdahl, B.; Teglbjaerg, C. et al

in Revue du Rhumatisme (2015, November), 82(S1), 123-124

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailEnergy and nutrient contents of food served and consumed by nursing home residents
Buckinx, Fanny ULg; Paquot, Nicolas ULg; Allepaerts, Sophie ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 28 (6 ULg)
Full Text
Peer Reviewed
See detailImpact of the frailty status on muscle mass and muscle strength of nursing home residents
Buckinx, Fanny ULg; Croisier, Jean-Louis ULg; Reginster, Jean-Yves ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailCorrelation between muscle mass and muscle strength among nursing home residents
Buckinx, Fanny ULg; Croisier, Jean-Louis ULg; Reginster, Jean-Yves ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailDevelopment and validation of a self-administrated quality of life questionnaire specific to sarcopenia: the SarQol
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Rizzoli, R. et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailQuality of life and physical components linked to sarcopenia: baseline data of the SarcoPhAge study
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in European Geriatric Medicine (2015, September), 6S1

Detailed reference viewed: 33 (5 ULg)